Changes in expression of apoptosis-related genes are linked to the molecular response to imatinib treatment in chronic-phase chronic myeloid leukemia patients

Acta Haematologica

Volumn 117, Issue 2, 2007, Pages 83-90

  Wei, Yuan ^a,b   Stockelberg, Dick ^a   Hullberg, Sara ^a   Ricksten, Anne ^a   Wadenvik, Hans ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; BAD; BAX; BCL XL; BCL XS; BCL2; BCR ABL; Chronic myelogenous leukemia; Imatinib

Indexed keywords

HEMOGLOBIN; IMATINIB; MESSENGER RNA;

ADULT; APOPTOSIS; ARTICLE; BAD GENE; BAX GENE; BCL XL GENE; BCL XS GENE; BCL2 GENE; BCR ABL GENE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKEMIA CELL; LEUKOCYTE COUNT; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STEM CELL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADULT; AGED; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33847084601     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096858     Document Type: Article

References (35)

1. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-1082.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
3. Lange T, Gunther C, Kohler T, Krahl R, Musiol S, Leiblein S, Al-Ali HK, van Hoomissen I, Niederwieser D, Deininger MW: High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 2003;101:2152-2155.
4. Igney FH, Krammer PH: Death and antideath: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-288.
5. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna JL: Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000;191:977-984.
6. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL: The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 2000;20:1179-1186.
7. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-325.
8. Wong S, McLaughlin J, Cheng D, Witte ON: Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood 2003;101:4088-4097.
9. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
10. Kurzrock R, Estrov Z, Kantarjian H, Talpaz M: Conversion of interferon-induced, longterm cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol 1998;16:1526-1531.
11. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC: Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000;95:62-66.
12. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-1432.
13. Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjoberg K, Wadenvik H, Ricksten A: Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate. Med Oncol 2004;21:349-358.
14. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
15. Apte SS, Mattei MG, Olsen BR: Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAX delta. Genomics 1995;26:592-594.
16. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: Bcl-x, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
17. Minn AJ, Boise LH, Thompson CB: Bcl-x(S) antagonizes the protective effects of Bcl-x(L). J Biol Chem 1996;271:6306-6312.
18. Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25:169-193.
19. Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, Miyazawa K, Jayaram HN, Boswell HS: Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 1993;82:1838-1847.
20. Sanchez-Garcia I, Grutz G: Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 1995;92:5287-5291.
21. Brumatti G, Weinlich R, Chehab CF, Yon M, Amarante-Mendes GP: Comparison of the anti-apoptotic effects of Bcr-Abl, Bcl-2 and Bcl-x(L) following diverse apoptogenic stimuli. FEBS Lett 2003;541:57-63.
22. Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar M: Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer 2001;91:1964-1972.
23. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T: Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994;13:764-773.
24. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCRABL in chronic myeloid leukemia. Blood 1994;83:2038-2044.
25. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF: Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987;328:342-344.
26. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD: STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000;95:2118-2125.
27. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B: Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 1997;16:6151-6161.
28. Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL: Punish the parent not the progeny. Blood 2005;105:1862-1866.
29. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284.
30. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ: Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-4707.
31. Kroemer G: The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997;3:614-620.
32. Adams JM, Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-1326.
33. Yang E, Korsmeyer SJ: Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88:386-401.
34. Ito T, Deng X, Carr B, May WS: Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997;272:11671-11673.
35. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-689.